This trial was conducted in Europe. The aim of this clinical trial was to look into the concentration of NN1250 (insulin degludec/insulin 454) in the blood after one injection of NN1250 in children, adolescents and adults with type 1 diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
39
0.4 U/kg body weight injected subcutaneously (under the skin), single dose
0.4 U/kg body weight injected subcutaneously (under the skin), single dose
Novo Nordisk Investigational Site
Hanover, Germany
Area under the NN1250 concentration-time curve after single dose
Time frame: 0-72 hours after dosing
Maximum observed NN1250 concentration after single dose
Time frame: 0-72 hours after dosing
Time to maximum observed NN1250 concentration after single dose
Time frame: 0-72 hours after dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.